Immunovia AB (Immunovia) is a molecular diagnostics company. It offers clinical testing for early diagnosis of pancreatic cancer. The company develops IMMray, a technology platform based on antibody microarray analysis which can be used in the early diagnosis of cancer, predicting disease progression, and monitoring the therapeutic responsiveness of cancers. Immunovia’s IMMray can also be used for biomarker discovery through its discovery tool for proteome scanning. The company also provides IMMray PanCan-d, a blood-based test for the detection of pancreatic cancer. Immunovia is headquartered in Lund, Sweden.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Immunovia AB
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Immunovia AB Company Overview
- Immunovia AB Company Snapshot
- Immunovia AB Pipeline Products and Ongoing Clinical Trials Overview
- Immunovia AB - Pipeline Analysis Overview
- Immunovia AB - Key Facts
- Immunovia AB - Major Products and Services
- Immunovia AB Pipeline Products by Development Stage
- Immunovia AB Ongoing Clinical Trials by Trial Status
- Immunovia AB Pipeline Products Overview
- IMMray - Breast Cancer
- IMMray - Breast Cancer Product Overview
- IMMray - NSCLC
- IMMray - NSCLC Product Overview
- IMMray - Prostate Cancer
- IMMray - Prostate Cancer Product Overview
- IMMray PanCan-d
- IMMray PanCan-d Product Overview
- IMMray PanCan-d Clinical Trial
- IMMray PanCan-m Test
- IMMray PanCan-m Test Product Overview
- IMMray Primary Sjogren’s Syndrome Assay
- IMMray Primary Sjogren’s Syndrome Assay Product Overview
- IMMray Rheumatoid Arthritis Assay
- IMMray Rheumatoid Arthritis Assay Product Overview
- IMMray SLE-d Test
- IMMray SLE-d Test Product Overview
- IMMray Systemic Vasculitis Assay
- IMMray Systemic Vasculitis Assay Product Overview
- Next Generation Pancreatic Cancer Detection Test
- Next Generation Pancreatic Cancer Detection Test Product Overview
- ProMIS Assay
- ProMIS Assay Product Overview
- Immunovia AB - Key Competitors
- Immunovia AB - Key Employees
- Immunovia AB - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Immunovia AB, Recent Developments
- Nov 07, 2023: Immunovia successfully completes discovery phase of next-generation test development
- Nov 02, 2023: Immunovia Announces Invitation to Q3 Presentation
- Aug 30, 2023: Immunovia Publishes Interim Report for January-June 2023
- Aug 23, 2023: Immunovia Announces Invitation for Q2 Presentation
- Jul 12, 2023: Immunovia to Significantly Restructure to Focus Resources on its Next-Generation Blood Test for Pancreatic Cancer Detection
- May 22, 2023: Immunovia: Changes to the nomination committee's proposal to the annual general meeting 2023
- Apr 26, 2023: Immunovia to discuss adoption of IMMray PanCan-d with key opinion leaders on May 3, 2023
- Apr 21, 2023: Immunovia announces annual report for 2022
- Apr 20, 2023: Immunovia to participate in National Pancreas Foundation Webinar on Biomarkers and Liquid Biopsy for early detection of pancreatic cancer
- Mar 16, 2023: Immunovia Announces Bulletin from the extraordinary general meeting
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Immunovia AB Pipeline Products and Ongoing Clinical Trials Overview
- Immunovia AB Pipeline Products by Equipment Type
- Immunovia AB Pipeline Products by Indication
- Immunovia AB Ongoing Clinical Trials by Trial Status
- Immunovia AB, Key Facts
- Immunovia AB, Major Products and Services
- Immunovia AB Number of Pipeline Products by Development Stage
- Immunovia AB Pipeline Products Summary by Development Stage
- Immunovia AB Ongoing Clinical Trials by Trial Status
- Immunovia AB Ongoing Clinical Trials Summary
- IMMray - Breast Cancer - Product Status
- IMMray - Breast Cancer - Product Description
- IMMray - NSCLC - Product Status
- IMMray - NSCLC - Product Description
- IMMray - Prostate Cancer - Product Status
- IMMray - Prostate Cancer - Product Description
- IMMray PanCan-d - Product Status
- IMMray PanCan-d - Product Description
- IMMray PanCan-d - A Prospective Evaluation of IMMray PanCan-d Biomarker Signature Assay in Subjects with New Onset Diabetes (NOD)
- IMMray PanCan-d - IMMray PanCan-d Utility in Patients with Abdominal Symptoms Attending Secondary Care Centres
- IMMray PanCan-m Test - Product Status
- IMMray PanCan-m Test - Product Description
- IMMray Primary Sjogren’s Syndrome Assay - Product Status
- IMMray Primary Sjogren’s Syndrome Assay - Product Description
- IMMray Rheumatoid Arthritis Assay - Product Status
- IMMray Rheumatoid Arthritis Assay - Product Description
- IMMray SLE-d Test - Product Status
- IMMray SLE-d Test - Product Description
- IMMray Systemic Vasculitis Assay - Product Status
- IMMray Systemic Vasculitis Assay - Product Description
- Next Generation Pancreatic Cancer Detection Test - Product Status
- Next Generation Pancreatic Cancer Detection Test - Product Description
- ProMIS Assay - Product Status
- ProMIS Assay - Product Description
- Immunovia AB, Key Employees
- Immunovia AB, Subsidiaries
- Glossary
- Immunovia AB Pipeline Products by Equipment Type
- Immunovia AB Pipeline Products by Development Stage
- Immunovia AB Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Active Biotech AB
- Moberg Pharma AB
- Alligator Bioscience AB
